Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB/ SE0000872095 /
SOBI
13.09.2024 17:29:40
|
Zm.
+5,80
|
Wolumen |
Bid17:29:40 |
Ask17:29:40 |
Kapitalizacja Rynkowa |
St. dywidendy |
Wskaźnik C/Z |
326,80SEK
|
+1,81%
|
249 500 Obrót: 72,6 mln |
327,20Wolumen Bid: 362 |
327,40Wolumen Ask: 49 |
115,8 mldSEK |
- |
43,75 |
Opis działalności
Swedish Orphan Biovitrum AB is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families.
Zarząd & Rada nadzorcza
CEO |
Guido Oelkers |
Zarząd |
Henrik Stenqvist, Lydia Abad-Franch, Duane H. Barnes, Lena Bjurner, Sofiane Fahmy, Torbjörn Hallberg, Mahmood Ladha, Norbert Oppitz, Daniel Rankin, Armin Reininger, Christine Wesström |
Rada nadzorcza |
Annette Clancy, Christophe Bourdon, Helena Saxon, Staffan Schüberg, Katy Mazibuko, Mats Lek, Anders Ullman, Filippa Stenberg |
Dane firmy
Nazwa: |
Swedish Orphan Biovitrum AB |
Adres: |
Tomtebodavägen 23A,Solna 112 76 |
Telefon: |
+46-8-697-2000 |
Fax: |
- |
E-mail: |
-
|
Internet: |
www.sobi.com |
Przemysł: |
Biotechnologia |
Sektor: |
Biotechnologia |
Podsektor: |
Biotechnologia |
Koniec roku finansowego: |
31.12 |
Free float: |
42,16% |
Data IPO: |
- |
Główni akcjonariusze
Inne |
|
38,50% |
Investor Aktiebolag |
|
34,70% |
Morgan Stanley Smith Barney Llc, W9 |
|
9,89% |
Fjärde AP-fonden |
|
5,93% |
State Street Bank And Trust Co, W9 |
|
4,27% |
Jp Morgan Chase Bank Na |
|
3,51% |
Northern Trust Company, London Branch |
|
3,20% |